Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Research and development biotechnology company ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, has completed a pilot animal study which suggests that an alternative to steroids may be possible in the future for asthma patients.
Subscribe to our email newsletter
The study was designed to determine whether the company’s proprietary substance, Homspera, is effaceable in blocking the development of airway hyperreactivity. The results indicate that Homespera could be used to attenuate an asthma attack caused as a result of toxic stimulation.
The study, conducted at the University of Arizona, was performed on 23 mice, seven of which were controls. The mice were divided into cigar or cigarette smoking groups and half of each received a daily aerosol treatment of Homspera.
Data from the trial demonstrate that the Homspera treatment can attenuate the development of airway hyperreactivity after toxic exposure to either cigarette or cigar smoke.
“After completing the study, we are very enthusiastic about the results,” stated Michael Wilhelm, CEO of ImmuneRegen BioSciences. “This first research study and its corresponding results show great potential for Homspera as a treatment for asthma. Although asthma is not currently the company’s focus, we are excited about adding it to our pipeline.”